Efficacy
of an Oral Insulin Spray (Oralin) Delivered Through The Buccal
Mucosa
A
combination of OralinTM and oral agents significantly increased the
insulin levels
For
years, diabetes researchers have searched for an alternative to
injected insulin. A study presented at the ENDO 2002 press
conference shows the efficacy of an oral insulin spray, called
OralinTM, which is delivered inside of the mouth through the buccal
mucosa, that has been developed by Generex Biotechnology
Corporation. Researchers studied the effects of OralinTM on 13
subjects with type-2 diabetes in combination with oral agents as
well as oral agents alone, and followed both by a 360-calorie meal.
“Our
data shows that a combination of OralinTM and oral agents
significantly increased the insulin levels,” said Dr. Jaime
Guevara-Aguirre, an Ecuadorian researcher who worked with researchers
from Generex on the study. “OralinTM also helped keep the glucose
and c-peptide levels lower when compared with oral agents alone.”
Dr.
Guevara-Aguirre noted the need for larger and longer studies to
further test the effectiveness of oral insulin spray.
Endo 2002
